Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP509485.RAauVnsQIco0I_AnbdMTVydy0riQ-t0pg6EHLvqX9Vmo8130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP509485.RAauVnsQIco0I_AnbdMTVydy0riQ-t0pg6EHLvqX9Vmo8130_assertion type Assertion NP509485.RAauVnsQIco0I_AnbdMTVydy0riQ-t0pg6EHLvqX9Vmo8130_head.
- NP509485.RAauVnsQIco0I_AnbdMTVydy0riQ-t0pg6EHLvqX9Vmo8130_assertion description "[Both infliximab (chimeric anti-tumor necrosis factor [TNF]-alpha antibody) and etanercept (p75 TNF-alpha receptor/immunoglobulin G fusion protein) are effective against rheumatoid arthritis, but only infliximab induces clinical remission in Crohn's disease.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP509485.RAauVnsQIco0I_AnbdMTVydy0riQ-t0pg6EHLvqX9Vmo8130_provenance.
- NP509485.RAauVnsQIco0I_AnbdMTVydy0riQ-t0pg6EHLvqX9Vmo8130_assertion evidence source_evidence_literature NP509485.RAauVnsQIco0I_AnbdMTVydy0riQ-t0pg6EHLvqX9Vmo8130_provenance.
- NP509485.RAauVnsQIco0I_AnbdMTVydy0riQ-t0pg6EHLvqX9Vmo8130_assertion SIO_000772 15685549 NP509485.RAauVnsQIco0I_AnbdMTVydy0riQ-t0pg6EHLvqX9Vmo8130_provenance.
- NP509485.RAauVnsQIco0I_AnbdMTVydy0riQ-t0pg6EHLvqX9Vmo8130_assertion wasDerivedFrom befree-20140225 NP509485.RAauVnsQIco0I_AnbdMTVydy0riQ-t0pg6EHLvqX9Vmo8130_provenance.
- NP509485.RAauVnsQIco0I_AnbdMTVydy0riQ-t0pg6EHLvqX9Vmo8130_assertion wasGeneratedBy ECO_0000203 NP509485.RAauVnsQIco0I_AnbdMTVydy0riQ-t0pg6EHLvqX9Vmo8130_provenance.